Myriad Genetics, Inc.
MYGNFinancial Statements
Income Statement (Annual)
Amounts in millions
2024
12/31/2024
Revenue
838
Cost of Revenue
252
Gross Profit
585
Gross Margin
69.9%
Operating Income
-124
Operating Margin
-14.7%
Net Income
-127
Net Margin
-15.2%
EPS (Basic)
$-1.41
EPS (Diluted)
$-1.41
EBITDA
-60
EBITDA Margin
-7.1%
2023
12/31/2023
Revenue
753
Cost of Revenue
236
Gross Profit
517
Gross Margin
68.6%
Operating Income
-257
Operating Margin
-34.2%
Net Income
-263
Net Margin
-35.0%
EPS (Basic)
$-3.18
EPS (Diluted)
$-3.18
EBITDA
-197
EBITDA Margin
-26.2%
2022
12/31/2022
Revenue
678
Cost of Revenue
202
Gross Profit
476
Gross Margin
70.2%
Operating Income
-141
Operating Margin
-20.7%
Net Income
-112
Net Margin
-16.5%
EPS (Basic)
$-1.39
EPS (Diluted)
$-1.39
EBITDA
-85
EBITDA Margin
-12.5%
2021
12/31/2021
Revenue
691
Cost of Revenue
198
Gross Profit
493
Gross Margin
71.4%
Operating Income
-191
Operating Margin
-27.6%
Net Income
-27
Net Margin
-3.9%
EPS (Basic)
$-0.35
EPS (Diluted)
$-0.35
EBITDA
12
EBITDA Margin
1.8%
2020
12/31/2020
Revenue
557
Cost of Revenue
178
Gross Profit
379
Gross Margin
68.0%
Operating Income
-195
Operating Margin
-35.0%
Net Income
-224
Net Margin
-40.2%
EPS (Basic)
$-2.99
EPS (Diluted)
$-2.99
EBITDA
-123
EBITDA Margin
-22.2%